top of page

Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company

  • Sep 29, 2025
  • 1 min read

CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measured, and what the learnings were from a handful of endpoints. Plus, Enanta's earlier stage I&I programs targeting KIT and STAT6.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page